Hypertension Diagnostics, Inc. issued a press release today to announce data that has been published in the American Journal of Epidemiology which indicates that the Hypertension’s CardioVascular Profiling Test is a more reliable and accurate predictor of hypertension than standard, more expensive procedures that are used today by physicians and cardiologists. The CardioVascular Profiling Test measures the elasticity of small blood vessels in a non-evasive manner. The Hypertension Diagnostics’ products capture blood pressure waveform data produced by the beating heart and analyze it to provide an assessment of systemic arterial elasticity for large and very small arteries.

The data was collected is an ongoing, 10-year study being conducted by Multi-Ethnic Study of Atherosclerosis (MESA) and sponsored by the National Heart, Lung, and Blood Institute (NHLBI). It includes over 6,000 participants of a variety of ethnicities, ages of 45-84 years, who were free of cardiovascular disease signs or symptoms. There were four different diagnostic technologies used to collect the data and study the participants, including the coronary computed tomography (CAT scan), carotid intimate media thickness test (carotid ultrasound), magnetic resonance imaging (MRI), and Hypertension Diagnostics’ non-invasive sensor called “CVProfilor.” The CVProfilor® utilizes Hypertension Diagnotics’ patented, proprietary waveform technology to take a reading of the radial artery at the wrist.

When the results from these tests were evaluated relative to the development of hypertension in the study population, Hypertension Diagnostics’ small artery elasticity index was shown to be the earliest predictor of incident hypertension. These findings confirm that measurement of small artery elasticity using HDI’s CVProfilor can predict hypertension. With hypertension affecting more than 30% of the United States population, detecting it at its earliest stages is critical. Hypertension can be linked to several other cardiovascular diseases. In fact, The American Heart Association estimates that nearly 73 million American adults have high blood pressure and that 36% of all deaths in the United States (as of 2004) can attribute cardiovascular disease as the underlying cause of death.

President of Hypertension Diagnostics, Inc., Greg Guettler, was quoted in the press release as saying, “The results of this large trial are unmistakable and potentially game-changing to the assessment of hypertension,” and “The data from this publication indicates that the CVProfilor arterial elasticity test can identify patients with hypertension better than and years earlier than more expensive imaging technology that has been considered the standard of care in patients at risk for cardiovascular disease. This study illustrates both the need and the benefit that can be derived from early cardiovascular disease detection.”